Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Leases (2019 - 2025)

Historic Operating Leases for Ironwood Pharmaceuticals (IRWD) over the last 7 years, with Q3 2025 value amounting to $10.5 million.

  • Ironwood Pharmaceuticals' Operating Leases fell 1850.64% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 1850.64%. This contributed to the annual value of $12.3 million for FY2024, which is 1539.57% down from last year.
  • Ironwood Pharmaceuticals' Operating Leases amounted to $10.5 million in Q3 2025, which was down 1850.64% from $11.1 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Operating Leases' 5-year high stood at $19.9 million during Q1 2021, with a 5-year trough of $10.5 million in Q3 2025.
  • Its 5-year average for Operating Leases is $15.4 million, with a median of $15.6 million in 2023.
  • In the last 5 years, Ironwood Pharmaceuticals' Operating Leases tumbled by 824.17% in 2021 and then tumbled by 1850.64% in 2025.
  • Ironwood Pharmaceuticals' Operating Leases (Quarter) stood at $18.5 million in 2021, then dropped by 10.2% to $16.6 million in 2022, then decreased by 12.39% to $14.5 million in 2023, then dropped by 15.4% to $12.3 million in 2024, then dropped by 14.68% to $10.5 million in 2025.
  • Its Operating Leases was $10.5 million in Q3 2025, compared to $11.1 million in Q2 2025 and $11.7 million in Q1 2025.